← Back
SAN GIOVANNI
December, 06th | 13:30 - 15:00
RETINA FUTURA - SESSION 2 - unconditional support of Ocular Therapeutix
Add to calendar
Chairs: RIZZO STANISLAO, HEIER JEFFREY S., KAISER PETER, VAJZOVIC LEJLA
December, 06th | 13:34 - 13:38
Glycomimetic Nanoparticle AVD-104 in the Management of GA From AMD: Anatomic Outcomes
HASSAN TAREK
Add to calendar
Glycomimetic Nanoparticle AVD-104 in the Management of GA From AMD: Anatomic Outcomes
HASSAN TAREK
Add to calendar
December, 06th | 13:38 - 13:42
OpRegen: Embryonic Stem Cell Derived Therapy for Dry AMD and GA
RIEMANN CHRISTOPHER D.
Add to calendar
OpRegen: Embryonic Stem Cell Derived Therapy for Dry AMD and GA
RIEMANN CHRISTOPHER D.
Add to calendar
December, 06th | 13:42 - 13:46
Fas Inhibition with ONL1204 for the Treatment of GA Secondary to AMD: Results from a Phase 1b Study
VAJZOVIC LEJLA
Add to calendar
Fas Inhibition with ONL1204 for the Treatment of GA Secondary to AMD: Results from a Phase 1b Study
VAJZOVIC LEJLA
Add to calendar
December, 06th | 13:46 - 13:50
C1q inhibition with ANX007: Functional and Structural Protection in dry AMD / GA via a Novel Neuroprotective Mechanism
KAISER PETER
Add to calendar
C1q inhibition with ANX007: Functional and Structural Protection in dry AMD / GA via a Novel Neuroprotective Mechanism
KAISER PETER
Add to calendar
December, 06th | 13:50 - 13:54
The Future of GA Treatment: Novel Pharmacotherapies in Development
WYKOFF CHARLES C.
Add to calendar
The Future of GA Treatment: Novel Pharmacotherapies in Development
WYKOFF CHARLES C.
Add to calendar
December, 06th | 14:00 - 14:04
Outcomes of the HORNBILL Study: Phase 1/2a Trial Investigating BI 764524 in Patients With Diabetic Macular Ischemia
NGUYEN QUAN DONG
Add to calendar
Outcomes of the HORNBILL Study: Phase 1/2a Trial Investigating BI 764524 in Patients With Diabetic Macular Ischemia
NGUYEN QUAN DONG
Add to calendar
December, 06th | 14:04 - 14:08
OCS-01: An emerging topical treatment option for DME
LOEWENSTEIN ANAT
Add to calendar
OCS-01: An emerging topical treatment option for DME
LOEWENSTEIN ANAT
Add to calendar
December, 06th | 14:12 - 14:16
HELIOS: Phase 1 SAFETY Study of AXPAXLI in NPDR
DHOOT DILSHER
Add to calendar
HELIOS: Phase 1 SAFETY Study of AXPAXLI in NPDR
DHOOT DILSHER
Add to calendar
December, 06th | 14:16 - 14:20
Intravitreal Fas inhibitor ONL1204 for Macula-off Rhegmatogenous Retinal Detachment: Results of a Phase 2 Clinical Trial
BORKAR DURGA
Add to calendar
Intravitreal Fas inhibitor ONL1204 for Macula-off Rhegmatogenous Retinal Detachment: Results of a Phase 2 Clinical Trial
BORKAR DURGA
Add to calendar
December, 06th | 14:30 - 14:34
ABBV-RGX-314: A one-time in-office gene therapy for the treatment of diabetic retinopathy and the prevention of DME, PDR & other vision threatening complications; the Phase II ALTITUDE® Study
VAJZOVIC LEJLA
Add to calendar
ABBV-RGX-314: A one-time in-office gene therapy for the treatment of diabetic retinopathy and the prevention of DME, PDR & other vision threatening complications; the Phase II ALTITUDE® Study
VAJZOVIC LEJLA
Add to calendar
December, 06th | 14:45 - 15:00
Session Awards - Newcomer of the Year Award - Most Innovative Science Award - Most Clinically Impactful Award
Add to calendar
Session Awards - Newcomer of the Year Award - Most Innovative Science Award - Most Clinically Impactful Award
Add to calendar